Home›Companies›Biotech & Pharma›Alumis

Alumis Inc.

Updated Oct 27, 2026·Latest SEC filing Mar 11, 2024·Suggest an edit

About Alumis

Alumis is a private company based in South San Francisco, California, incorporated in 2021 in Delaware. It has reported $199,999,957 raised in three offerings on Form D since February 2021. Its chief executive is Martin Babler.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Mar 4, 2024Mar 11, 2024$129,499,957of $258.9M target24$5.3MEquityRule 506(b)Form D ↗
Mar 4, 2021Mar 19, 2021$60,000,000fully sold3$20.0MEquity, Debt, OptionsRule 506(b)Form D ↗
Feb 12, 2021Feb 25, 2021$10,500,000fully sold3$3.5MEquityRule 506(b)Form D ↗
Total, three offerings$199,999,957

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Alumis's Form D filed Mar 11, 2024.

ZY
Zhengbin Yao
Director
SS
Sapna Srivastava
Director
Also an executive officer at eGenesis.
MB
Martin Babler
CEO and director
AC
Alan Colowick
Director
Also a director at Recode Therapeutics.
JB
Julian Baker
Director
JT
James Tananbaum
Director
Also a director at Latigo Biotherapeutics.

Earlier filings also listed Michael Rome (director, last listed Mar 2021), June Lee (chief executive officer and director, last listed Mar 2021) and Vikram Bajaj (director, last listed Feb 2021).

Sources

  1. SECALUMIS INC. filing history